The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Cleveland health officials are warning residents after a 250% spike in COVID-19 viral levels was found in city wastewater.